Ovarian Cancer’s Hidden Weakness: An Arginine Gateway on the Cell Surface

High-grade serous ovarian cancer remains one of the most lethal malignancies affecting women, a grim distinction driven largely by the fact that current treatments rarely produce durable remissions. Surgery and platinum-based chemotherapy can shrink tumors impressively at first, but the disease almost invariably returns in a form that resists further therapy. Against this backdrop, researchers in Toronto have taken a fresh look at an underexplored class of drug targets: the proteins that stud the outer surface of cancer cells. In a study published in Genome Biology, a team led by Thomas Kislinger at the Princess Margaret Cancer Centre and the University of Toronto mapped the surface proteome of high-grade serous ovarian cancer cells in unprecedented detail, and in doing so uncovered a surprising metabolic vulnerability centered on the amino acid arginine.

The logic behind targeting the cell surface is straightforward but technically demanding. Surface proteins are the molecular gatekeepers of a cell, controlling what enters and exits, transmitting growth signals, and mediating interactions with neighboring tissue. Because they protrude from the membrane, they are accessible to antibodies and other drugs circulating in the bloodstream, making them far more tractable pharmacologically than proteins buried inside the nucleus or cytoplasm. Yet despite this appeal, the surface landscape of high-grade serous ovarian cancer had never been systematically cataloged, leaving potentially decisive targets invisible to drug developers.

To build that catalog, the team employed a technique known as cell surface N-glycoproteomics. The method exploits the fact that most surface proteins carry sugar chains, called glycans, attached to asparagine residues on the portions of the protein facing the outside of the cell. By using an enzyme that specifically clips these glycosylated segments and then identifying the released peptides by high-resolution mass spectrometry, researchers can enrich for and precisely quantify the proteins displayed on the cell exterior. This approach filters out the overwhelming noise of intracellular proteins that dominate whole-cell proteomic measurements, providing a focused portrait of what the cancer cell actually presents to its environment.

The comparison was designed with therapeutic discrimination in mind. The researchers profiled not only high-grade serous ovarian cancer cell lines but also normal epithelial cells derived from the fallopian tube, the tissue of origin for this cancer type, as well as cancer-associated stromal cells that form the tumor’s supporting infrastructure. A surface protein that appears abundantly on cancer cells but is scarce or absent on normal tissue represents an ideal drug target, because therapies aimed at it would preferentially attack the tumor while sparing healthy cells. Cross-referencing the resulting surface protein profiles with data from The Cancer Genome Atlas helped confirm which candidates were consistently elevated across patient tumors rather than being artifacts of cell culture.

The screen surfaced a striking finding: 274 proteins were enriched on the surface of high-grade serous ovarian cancer cells relative to the normal and stromal controls. Many of these were poorly characterized, their functions in cancer entirely unstudied. To determine which of them actually mattered for the disease, the team integrated their proteomic data with functional genetic screening, systematically reducing the expression of each candidate and measuring the consequences for cancer cell proliferation. This convergence of measurement and perturbation is what elevates the study from a descriptive atlas to a prioritized target list, distinguishing proteins that merely decorate the cancer cell from those the cancer genuinely depends upon.

One protein rose decisively to the top: SLC7A1, also known as CAT-1, a transporter embedded in the cell membrane whose job is to import arginine from the extracellular environment. The functional experiments showed that when SLC7A1 was depleted, high-grade serous ovarian cancer cells suffered across multiple fronts simultaneously. Their proliferation slowed, their ability to migrate, a capability central to the metastatic spread that makes this disease so deadly, was impaired, and their protein synthesis machinery faltered. Mitochondrial function, the engine room of cellular energy production, also deteriorated in the absence of the transporter, painting a picture of a cancer cell whose metabolic architecture is built around a steady supply of imported arginine.

Why would an aggressive cancer become so dependent on a single amino acid transporter? The answer appears to lie in the peculiar chemistry of arginine itself. Beyond its role as a building block for proteins, arginine feeds into multiple biosynthetic and signaling pathways: it is a precursor for the synthesis of polyamines that drive cell growth, a substrate for the production of nitric oxide that influences vascular tone and signaling, and a contributor to the maintenance of mitochondrial metabolism. Cancer cells with voracious growth demands often rewire their metabolism to secure abundant arginine, and the new findings indicate that high-grade serous ovarian cancer accomplishes this, at least in part, by elevating SLC7A1 on its surface. Multi-omic analyses in the study linked the transporter’s abundance to a broader dysregulation of arginine metabolism within the tumors.

The therapeutic implications are tantalizing because arginine dependency is a vulnerability that can be attacked from outside the cell. An enzyme called arginine deiminase, which depletes arginine from the blood, has already been explored in clinical trials for other arginine-hungry cancers, and the new work provides a rationale for testing such strategies in ovarian cancer patients whose tumors display high surface levels of SLC7A1. Alternatively, antibodies or small molecules directed at the transporter itself could, in principle, starve the tumor while leaving normal cells, which express far less of the protein, largely unaffected. The study’s authors are careful to frame these as putative avenues, but the combination of a cancer-specific surface target, a defined metabolic mechanism, and existing pharmacological tools is a rare and valuable alignment.

Equally important is the framework the study establishes for the future. By demonstrating that cell surface N-glycoproteomics, integrated with functional screening and validated against patient data, can convert an unexplored proteomic landscape into a ranked list of dependencies, the Toronto team has created a template that can be applied to other lethal cancers whose surface biology remains unmapped. Several of the other 273 enriched proteins identified in the screen remain minimally characterized, and each represents a potential lead for follow-up investigation. For a disease in which the therapeutic arsenal has barely expanded in decades, the discovery that a single arginine transporter sits at the intersection of proliferation, migration, and mitochondrial health offers both an immediate target and a persuasive argument that the surfaces of cancer cells still hold secrets worth mining.

Subject of Research: Cell surface proteomics identifies the arginine transporter SLC7A1 as a therapeutic vulnerability in high-grade serous ovarian cancer

Article Title: Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancer

Article References: Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancer. (n.d.). https://doi.org/10.1186/s13059-026-04294-6

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04294-6

Keywords: high-grade serous ovarian cancer, surface proteomics, SLC7A1, arginine metabolism, cell surface N-glycoproteomics, mass spectrometry, cancer metabolism, therapeutic targets, arginine deiminase, mitochondrial function, Princess Margaret Cancer Centre, Genome Biology